Please use this identifier to cite or link to this item: doi:10.22028/D291-46320
Title: Overcoming limitations in exhaled breath aerosol analysis - Untargeted breathomics for the identification of endogenous breath biomarkers using LC-HRMS/MS
Author(s): Maalouli Schaar, Juel
Hemmer, Selina
Manier, Sascha K.
Wagmann, Lea
Meyer, Markus R.
Language: English
Title: Analytica Chimica Acta
Volume: 1365
Publisher/Platform: Elsevier
Year of Publication: 2025
Free key words: Exhaled breath
Untargeted breathomics
Endogenous biomarker
LC-HRMS/MS
DDC notations: 610 Medicine and health
Publikation type: Journal Article
Abstract: Background Human exhaled breath (EB) aerosol is a suitable matrix for the non-invasive bioanalysis of both volatile but also non-volatile compounds. One of the key challenges in drug monitoring studies is the lack of standardization in EB sample collection. The aim of the present study was to use untargeted breathomics for identification of potential endogenous biomarkers in EB that could address these challenges. Results The Breath Explor impaction device was used to collect microparticles in EB aerosol from six healthy volunteers and six different sampling time points over a 1-h period (total number of samples = 36). Sample preparation consisted of an extraction with methanol and analysis was performed using reversed-phase and hydrophilic interaction-phase liquid chromatography coupled to high-resolution mass spectrometry. Results revealed the presence of a feature that could be reliably detected across all samples, thus representing a potential biomarker for standardizing EB aerosol sample collection. Although an annotation of this feature was not possible, it showed robustness and reproducibility in EB samples from healthy volunteers and could also be successfully detected in patient samples. Significance and novelty This study represents a step forward in overcoming the current limitation of EB analysis, the lack of standardization in sampling procedure. Nevertheless, further investigation including correlation studies and more diverse populations will be essential for the confirmation of the clinical relevance and application of this biomarker.
DOI of the first publication: 10.1016/j.aca.2025.344241
URL of the first publication: https://doi.org/10.1016/j.aca.2025.344241
Link to this record: urn:nbn:de:bsz:291--ds-463204
hdl:20.500.11880/40596
http://dx.doi.org/10.22028/D291-46320
ISSN: 0003-2670
Date of registration: 24-Sep-2025
Description of the related object: Supplementary data
Related object: https://ars.els-cdn.com/content/image/1-s2.0-S000326702500635X-mmc1.xlsx
https://ars.els-cdn.com/content/image/1-s2.0-S000326702500635X-mmc2.pdf
Faculty: M - Medizinische Fakultät
Department: M - Experimentelle und Klinische Pharmakologie und Toxikologie
Professorship: M - Prof. Dr. Markus Meyer
Collections:SciDok - Der Wissenschaftsserver der Universität des Saarlandes

Files for this record:
File Description SizeFormat 
1-s2.0-S000326702500635X-main.pdf1,28 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons